

Dermal Toxicology Specialty Section

Executive Council

President

Jim E. Riviere, DVM, Ph.D.
North Carolina State University
jim_riviere@ncsu.edu

President-Elect

Ian Kimber, Ph.D.
Syngenta
ian.kimber@syngenta.com

Vice-President

Nancy Monteiro-Riviere, Ph.D.
North Carolina State University
nancy_monteiro@ncsu.edu

Secretary-Treasurer

Dee Sailstad, MSPH
USEPA
Immunotoxicology Branch
sailstad.denise@epamail.epa.gov

Counselors

G. Frank Gerberick, Ph.D.
Procter & Gamble
gerberick.gf@pg.com

B. Jean Meade, Ph.D.

CDC/NIOSH
bhm8@cdc.gov


Cindy A. Ryan

Procter & Gamble
ryan.ca@pg.com

The *Dermal Toxicology Specialty Section* newsletter is published 3 times/year (March, July, November) in electronic format. If you would like to share a book review, meeting report, web site, or any other item of general interest to the specialty section, please send it to the editors by the beginning of the month prior to the listed publication dates. We also welcome any comments or suggestions pertaining to overall content or format.

Michael K. Robinson, Editor
The Procter & Gamble Co.
Cincinnati, Ohio 45253
Tel. 53-627-2192; Fax. 513-627-0400
robinson.mk@pg.com

Lisa K. Ryan, Associate Editor
UMDNJ
Newark, NJ 07103
Tel. 973-972-2624
ryanlk@umdnj.edu



President's Message

I am pleased to report that the DTSS remains a strong and viable specialty section, largely due to the solid foundation built by past officers and members. This year is one of transition for SOT relations with its specialty sections as the national headquarters increases section dues and changes how it finances our operations. As part of this effort, headquarters promises to improve communication, their accounting of membership rosters and administrative support for specialty sections. As of an August 14th mailing, DTSS has 82 members, similar to last year's total despite an increase in dues.

Specialty sections are a crucial component of SOT's national meetings as they are responsible for the programs presented. Similarly, the specialty sections play a primary role in providing incentives for student members through their awards for meritorious papers presented at the national meeting. DTSS is active in all of these areas. Two of DTSS-sponsored program proposals have been accepted for presentation at the 2003 meeting in Salt Lake City. They are "Cutaneous Toxicity – Current Methods and Concepts in Safety Evaluation; Relevance to Human Exposure" and "Dermal Exposure Leading to Respiratory Tract Sensitization and Disease: A Trivial

or Critical Link?" Please plan to attend these sessions.

A number of initiatives are being worked on by our current officers. Please read about these in this newsletter and help make their efforts successful. Vice President Ian Kimber leads up this year's program committee which will look for proposals for the 2004 annual meeting. Councilor Jean Meade is chair of our student awards committee. I urge all members to encourage eligible students to apply. Councilor Cindy Ryan has responsibility for recruitment of new members. Any current DTSS members whom have associates working in this field are likewise encouraged to have them join our section. Secretary-Treasurer Dee Sailstad is the keeper of the books and minutes of all meetings. Past-President Frank Gerberick heads up our nomination committee whom will be looking for suitable candidates for next year's election. DTSS is greatly indebted to the services of Mike Robinson as Editor of this Newsletter.

Fall is the season when SOT Specialty Section activities heat up. I challenge all officers and members to work to make DTSS contribution to the 2004 annual meeting a success. See you in Salt Lake City!

Jim E. Riviere
Jim_Riviere@ncsu.edu

Treasurer's Report

Half-Full View:

As a relatively new specialty section in SOT it is important that we focus on the financial status of DTSS. Based on our last report,

Committee Updates

Membership Committee

Submitted by Cindy Ryan

Another summer has passed by quickly and its now that time of year when we begin to think about submitting abstracts for next years SOT meeting (incidentally, the electronic submission deadline is Oct.1) and renewing our SOT and specialty section memberships (SOT will be mailing out the 2003 annual membership renewal forms this fall). As you know, there have been issues in the past with SOT headquarters accounting of specialty section memberships. Therefore, when you receive your renewal form it is important that you:

Check the box for renewing your DTSS membership. Under SOT by-laws, in order to be a viable specialty section we must maintain a roster of at least 50 members.

Include the specialty section fee for your DTSS membership in the amount remitted to SOT. This may sound a little odd, but according to SOT headquarters, people often check the box for a particular specialty section but fail to include the \$25 fee in their payment. If you don't pay, you won't be counted as a member. Student and post-doctoral members are permitted to join one specialty section for free.

Pay your dues on time. Late payments received by SOT can be 'misplaced' when specialty section memberships are tallied. So even if you've paid to be a DTSS member, you may not be included in the official membership roster if your payment is late.

Keep a record of your payment. Whether you pay by check or credit card, keep some type of information to prove that you paid your dues. It's a good idea to also keep a copy of your completed membership form. That way, you will be able verify that you are a DTSS member if your name does not appear on the DTSS membership list that we receive from SOT headquarters

And, as always....

Encourage your colleagues (and students) to join the DTSS. We must continue to grow our specialty section membership. Wouldn't it be great for the DTSS to reach a total of 100 members this year? I believe that it can – if every current member recruited just one new member.

One final thing, **the membership committee needs volunteers.** At the specialty section social gathering in Nashville, no names were recorded on the membership committee sign-up sheet. Please consider joining the committee. If you have ideas or suggestions for recruiting I'd love to hear them. Remember, if your contact information, including your e-mail address, changes, send me a note at my e-mail address.

Cindy A. Ryan
ryan.ca@pg.com

Awards Committee

Submitted by Jean Meade

The time is approaching to submit applications for the Dermal Toxicology Specialty Section student/post-doc awards. Two awards will be given this year to recognize students conducting outstanding research in the areas of skin toxicology and pharmacology. Students should submit a copy of the abstract of their work (poster or platform presentations), which will be presented at the national SOT meeting in Salt Lake City. Winners will be announced at the annual meeting of the Dermal Toxicology Specialty Section and each will receive a certificate and a cash award. The deadline for submission of abstracts for consideration is February 9, 2003. Electronic submissions are preferred. Abstracts should be sent to:

Dr. Jean Meade
bhm8@cdc.gov

Dr. Jim Riviere
Jim_Riviere@ncsu.edu


Mentors please make your students are aware of these awards and encourage them to apply.

DTSS had only \$754 in July 2001. SOT headquarters gave a one-time "new section" adjustment of \$1,746 to DTSS so that we could begin the 2001-2002 year with \$2,500. The graphs below demonstrate our ordinary income and expenses for the year. The income, which includes funds from contribution, dues and interest, yielded \$2,590. Our total expenses were \$2,466. These expenditures were for awards, the reception and executive meeting. The DTSS net assets for the end of the year (June 2002) were \$2,624.


Half-Empty View:

While this amount may seem ample, it is important to remember that without the contributions from the General Fund we would have only \$124! Please take a look at the areas and percentages for both our income and expenditures. The financial stability of the section will require that we continue to bring in contributions from organizations when possible and build a strong membership. I reiterate Cindy Ryan's encouragement (see below) to pay dues and continue to encourage all potential new members to join DTSS. We will also keep close tabs on our expenditures for our July 2002 – June 2003 fiscal year.

DTSS Expenses July 2001 - June 2002



DTSS Income July 2001 - June 2002



Dee Sailstad
sailstad.denise@epamail.epa.gov

Communications Committee

Submitted by Michael K. Robinson

The goal of the Communications Committee of the DTSS is to coordinate the collection and dissemination of information relevant to the needs of dermal toxicologists within the specialty section, as well as assisting the Council in outreach to the general toxicology community. We do so through the use of a specialty section newsletter and an SOT-linked web site.

The newsletter is published 3 times each year (although the March and July 2002 issues were skipped due to lack of submissions) and contains reports from the president, committee updates, job postings, member news, member honors and awards, and member publications. The newsletter is sent to all members by email and is posted to the web site. The web site includes postings of the DTSS by-laws, current DTSS membership, current DTSS council members, special announcements, the annual report, a President's Corner, and the current and previous DTSS newsletters.

Note: We are aware that some of the currently posted web site information is outdated. Updated information will be sent to SOT for posting as soon as possible.

Michael K. Robinson, Chair
robinson.mk@pg.com
Lisa K. Ryan, Co-Chair
ryanlk@umd.nj.edu

Post-Doctoral Position Dermatotoxicology

The Center for Cutaneous Toxicology and Residue Pharmacology (CCTRP) at North Carolina State University (<http://cctrp.ncsu.edu>) is primarily involved in assessing percutaneous absorption and cutaneous toxicology of chemical mixtures of topically applied drugs and chemical mixtures. Novel statistical approaches have been developed to assess these multi-component interactions and to develop a simple but robust modeling approach that could be used to extrapolate these findings to *in vivo* human exposure. Individuals with a PhD or D.V.M. and expertise

& experience in one or several of the following areas are encouraged to apply: dermal absorption and cutaneous toxicity, skin cell biology, cell culture and utilization of molecular biology techniques pertinent to skin cell biology and evaluation of the effects of chemical mixtures. The position offers competitive salary and benefits. NCSU is located just minutes from Research Triangle Park, an internationally recognized center for biomedical research. Substantial collaborations between the CCTRP, neighboring Universities, national research laboratories, and major pharmaceutical companies are on going.

Technical questions may be directed to Dr. Nancy Monteiro-Riviere (Nancy_Monteiro@ncsu.edu). For preliminary screening, individuals should provide via email the following: curriculum vitae, list of publications, along with three references and a concise statement of research accomplishments. Position open until filled.

Toxicology Position Dow Corning

Position:
Toxicology specialist

Job Location:
Midland, Michigan

Job Summary:
Dow Corning, a U.S. based, multinational corporation and global leader in the silicon-based industry, seeks an experienced MS/PhD Toxicology Study Director for a position at our Midland, Michigan global headquarters.

Position Responsibilities:
This position is responsible for the oversight of Pharmacokinetic and Metabolism studies within the Toxicology Laboratory. Successful candidates will be expected to design, conduct and interpret studies in support of Dow Corning and external customers. Research areas of special interest include, but are not limited to: pharmacokinetics, metabolism and physiological modeling. Individuals with demonstrated productivity in

conducting pharmacokinetic and metabolism studies, good organizational skills and the ability to prioritize projects and customer requests are especially encouraged to apply.

Experience and Skill Requirements:

- 5+ years of experience in the Pharmacokinetics and Metabolism area.
- Study Director/Study Monitor experience.
- Good organizational skills with the ability to prioritize projects and customer requests.
- Report and manuscript writing experience.
- Good oral communication skills.
- Computer skills, including MS Word, Excel and PowerPoint.
- Experience with physiological modeling is desirable.

Educational/Professional Background:

MS/PhD in Pharmacokinetics, or related discipline, with 5+ years training and experience as a Study Director/Study Monitor in the Pharmacokinetics and Metabolism area.

Compensation/Benefits:

We offer a competitive compensation and benefits package and a relocation assistance program.

How to Apply:

Interested candidates should submit a cover letter, curriculum vitae, a list of publications and contact information for three references in to:

E-Mail:

docm4@apply.nationjob.com

HR Service Center/Staffing
Dow Corning Corporation
Mail No. HRSC-ToxSpec
P.O. Box 994
Midland, MI 48686-0994

Fax: [989-496-6109](tel:989-496-6109)

When applying for this position, you must refer to:

Member Publications

Each newsletter will feature a listing of specialty section member publications (journal articles, book chapters, books) that have appeared in print since the last edition. While the editors will do their best to survey the indexing services relative to the current membership roster, it is likely that some mistakes and omissions will occur. This is particularly true for books and book chapters. If we have inadvertently omitted a recent publication or listed something incorrectly, please advise us by email and we will see that this is corrected in the following newsletter. Also, we welcome your help in this endeavor. Please send us your citations for any recently published articles and books. That will aid us in our literature searching. Thank you - eds.

Recent Publications (DTSS authors in bold):

Api AM. Sensitization methodology and primary prevention of the research institute for fragrance materials. *Dermatology* 205:84-87, 2002.

Hawkins DR, Elsom LF, Kirkpatrick D, Ford RA, **Api AM.** Dermal absorption and disposition of musk ambrette, musk ketone and musk xylene in human subjects. *Toxicol Lett* 131:147-151, 2002.

Basketter DA, Evans P, Gerberick GF, Kimber IA. Factors affecting thresholds in allergic contact dermatitis: safety and regulatory considerations. *Contact Dermatitis*. 47:1-6, 2002.

Smith Pease CK, White IR, **Basketter DA.** Skin as a route of exposure to protein allergens. *Clin Exp Dermatol*. 27:296-300, 2002.

Smith HR, Armstrong DK, Holloway D, Whittam L, **Basketter DA, McFadden JP.** Skin irritation thresholds in hairdressers: implications for the development of hand dermatitis. *Br J Dermatol*. 146:849-852, 2002.

Dearman RJ, Caddick H, Stone S, Kenna JG, **Basketter DA, Kimber I.** Immunogenic properties of rapidly digested food proteins following gavage exposure of mice: a comparison of ovalbumin with a potato acid phosphatase preparation. *Food Chem Toxicol*. 40:625-

633, 2002.

Basketter DA, Evans P, Fielder RJ, Gerberick GF, Dearman RJ, Kimber I. Local lymph node assay - validation, conduct and use in practice. *Food Chem Toxicol*. 40:593-598, 2002.

Smith HR, **Basketter DA, McFadden JP.** Irritant dermatitis, irritancy and its role in allergic contact dermatitis. *Clin Exp Dermatol*. 27:138-146, 2002.

Baynes RE, Monteiro-Riviere NA, Riviere JE. Pyridostigmine bromide modulates the dermal disposition of [¹⁴C]permethrin. *Toxicol Appl Pharmacol*. 181:164-173, 2002.

Baynes RE, Brooks JD, Mumtaz M, Riviere JE. Effect of Chemical Interactions in Pentachlorophenol Mixtures on Skin and Membrane Transport. *Toxicol Sci*. 2002 Oct;69(2):295-305, 2002.

Sieben S, Kawakubo Y, Al Masaoudi T, Merk HF, **Blomeke B.** Delayed-type hypersensitivity reaction to paraphenylenediamine is mediated by 2 different pathways of antigen recognition by specific alpha beta human T-cell clones. *J Allergy Clin Immunol* 109:1005-1111, 2002.

Usmani KA, Rose RL, Goldstein JA, Taylor WG, **Brimfield AA, Hodgson E.** In vitro human metabolism and interactions of repellent N,N-diethyl-m-toluamide. *Drug Metab Dispos* 30:289-294, 2002.

Gad SC. Fifth triennial toxicology salary survey. *Int J Toxicol*. 1:323-328, 2002.

Hulette BA, **Ryan CA, Gerberick GF.** Elucidating changes in surface marker expression of dendritic cells following chemical allergen treatment. *Toxicol Appl Pharmacol*. 182:226-233, 2002.

Ryan C, Cruse L, Skinner R, Dearman R, Kimber I, Gerberick G. Examination of a vehicle for use with water soluble materials in the murine local lymph node assay. *Food Chem Toxicol*. 40:1719-1725, 2002.

Gerberick GF, Cruse LW, Ryan CA, Hulette BC, Chaney JG, Skinner RA, Dearman RJ, Kimber I. Use of a B Cell Marker (B220) to Discriminate between Allergens and Irritants in the Local Lymph Node Assay. *Toxicol Sci*. 68:420-428, 2002.

Roggeband R, Helmlinger G, Smith I, Wilhelm KP, **Ryan CA, Gerberick GF.** A skin sensitization safety assessment of a new bleach activator technology in detergent applications. *Contact Dermatitis*. 46:211-219, 2002.

Trouba KJ, Hamadeh HK, Amin RP, **Germolec DR.** Oxidative stress and its role in skin disease. *Antioxid Redox Signal*. 4:665-673, 2002.

Karrow NA, Guo TL, Leffel EK, Zhang LX, McCay JA, **Germolec DR, White KL Jr.** Sodium metasilicate hypersensitivity in BALB/c mice. *Am J Contact Dermat*. 13:133-139, 2002.

Guo TL, White KL Jr, Brown RD, Delclos KB, Newbold RR, Weis C, **Germolec DR, McCay JA.** Genistein modulates splenic natural killer cell activity, antibody-forming cell response, and phenotypic marker expression in F(0) and F(1) generations of Sprague-Dawley rats. *Toxicol Appl Pharmacol*. 181:219-227, 2002.

Cooper GS, Miller FW, **Germolec DR.** Occupational exposures and autoimmune diseases. *Int Immunopharmacol*. 2:303-313, 2002.

Van Miller JP, **Hermansky SJ, Losco PE, Ballantyne B.** Chronic toxicity and oncogenicity study with glutaraldehyde dosed in the drinking water of Fischer 344 rats. *Toxicology* 175:177-189, 2002.

Howell MD, Weissman DN, Jean Meade BJ. Latex sensitization by dermal exposure can lead to airway hyperreactivity. *Int Arch Allergy Immunol* 128:204-211, 2002.

Dearman RJ, Filby A, Humphreys IR, **Kimber I.** Interleukins 5 and 13 characterize immune responses to respiratory sensitizing acid anhydrides. *J Appl Toxicol* 22:317-325, 2002.

Kimber I. Danger signals and skin sensitization. *Br J Dermatol*. 147:613, 2002.

Karbe E, Williams GM, Lewis RW, **Kimber I, Foster PM.** Distinguishing between adverse and non-adverse effects. Session summary. *Exp Toxicol Pathol*. 54:51-55, 2002.

Hasmall S, Orphanides G, James N, Pennie W, Hedley K, Soames A, **Kimber I, Roberts R.** Downregulation of Lactoferrin by PPARalpha Ligands: Role in Perturbation of Hepatocyte Proliferation and Apoptosis. *Toxicol Sci*. Aug;68(2):304-313, 2002.

Cumberbatch M, Dearman RJ, Groves RW, Antonopoulos C, **Kimber I.** Differential regulation of epidermal langerhans cell migration by interleukins (IL)-1alpha and IL-1beta during irritant- and allergen-induced cutaneous immune responses. *Toxicol Appl Pharmacol*. 182:126-135, 2002.

Kimber I, Dearman RJ. Approaches to assessment of the allergenic potential of novel proteins in food from genetically

modified crops. *Toxicol Sci.* 68:4-8, 2002.

Kimber I, Dearman RJ. Immunologic basis for autoimmunity and the potential influences of xenobiotics. *Toxicol Lett.* 127:77-81, 2002.

Atherton KT, Dearman RJ, **Kimber I**. Protein allergenicity in mice: a potential approach for hazard identification. *Ann N Y Acad Sci.* 964:163-171, 2002.

Pennie WD, Kimber I. Toxicogenomics; transcript profiling and potential application to chemical allergy. *Toxicol In Vitro.* 16:319-326, 2002.

Cumberbatch M, Dearman RJ, **Kimber I**. Influence of ageing on Langerhans cell migration in mice: identification of a putative deficiency of epidermal interleukin-1beta. *Immunology.* 105:466-477, 2002.

Elcombe CR, Odum J, Foster JR, Stone S, Hasmall S, Soames AR, **Kimber I**, Ashby J. Prediction of rodent nongenotoxic carcinogenesis: evaluation of biochemical and tissue changes in rodents following exposure to nine nongenotoxic NTP carcinogens. *Environ Health Perspect.* 110:363-375, 2002.

Kimber I, Dearman RJ. Allergic contact dermatitis: the cellular effectors. *Contact Dermatitis.* 2002 46:1-5, 2002.

Kimber I, Cumberbatch M, Dearman RJ, Headon DR, Bhushan M, Griffiths CE. Lactoferrin: influences on langerhans cells, epidermal cytokines, and cutaneous inflammation. *Biochem Cell Biol.* 80:103-107, 2002.

Warbrick EV, Dearman RJ, **Kimber I**. IgG and IgE antibody responses following exposure of Brown Norway rats to trimellitic anhydride: comparison of inhalation and topical exposure. *Toxicology.* 172:157-168, 2002.

Kimber I, Dearman RJ. Immune responses: adverse versus non-adverse effects. *Toxicol Pathol.* 30:54-58, 2002.

Bhushan M, Cumberbatch M, Dearman RJ, Andrew SM, **Kimber I**, Griffiths CE. Tumour necrosis factor-alpha-induced migration of human Langerhans cells: the influence of ageing. *Br J Dermatol.* 146:32-40, 2002.

Warbrick EV, Dearman RJ, **Kimber I**. Induced changes in total serum IgE concentration in the Brown Norway rat: potential for identification of chemical respiratory allergens. *J Appl Toxicol.* 22:1-11, 2002.

Billack B, Heck DE, Mariano TM, Gardner CR, Sur R, **Laskin DL**, **Laskin JD**. Induction of cyclooxygenase-2 by heat shock protein 60 in macrophages and

endothelial cells. *Am J Physiol Cell Physiol.* 283:C1267-1277, 2002.

Laskin DL, Fakhrazadeh L, Heck DE, Gerecke D, **Laskin JD**. Upregulation of phosphoinositide 3-kinase and protein kinase B in alveolar macrophages following ozone inhalation. role of NF-kappaB and STAT-1 in ozone-induced nitric oxide production and toxicity. *Mol Cell Biochem.* 234-235:91-98, 2002.

Martey CA, Vetrano AM, Whittemore MS, Mariano TM, Gentile SL, Heck DE, **Laskin DL**, Heindel ND, **Laskin JD**. Mechanisms of growth inhibition in keratinocytes by mercurio-substituted 4',5'-dihydroxyresorcinol. *Biochem Pharmacol.* 63:2001-2009, 2002.

Chiu H, Brittingham JA, **Laskin DL**. Differential induction of heme oxygenase-1 in macrophages and hepatocytes during acetaminophen-induced hepatotoxicity in the rat: effects of hemin and biliverdin. *Toxicol Appl Pharmacol.* 181:106-115, 2002.

Ahmad N, Chen LC, Gordon MA, **Laskin JD**, **Laskin DL**. Regulation of cyclooxygenase-2 by nitric oxide in activated hepatic macrophages during acute endotoxemia. *J Leukoc Biol.* 71:1005-1011, 2002.

Weinberger B, **Laskin DL**, Heck DE, **Laskin JD**. Oxygen toxicity in premature infants. *Toxicol Appl Pharmacol.* 2002 181:60-67, 2002.

Dambach DM, Watson LM, Gray KR, **Durham SK**, **Laskin DL**. Role of CCR2 in macrophage migration into the liver during acetaminophen-induced hepatotoxicity in the mouse. *Hepatology.* 35:1093-1103, 2002.

Fakhrazadeh L, **Laskin JD**, **Laskin DL**. Deficiency in inducible nitric oxide synthase protects mice from ozone-induced lung inflammation and tissue injury. *Am J Respir Cell Mol Biol.* 26:413-419, 2002.

Sunil VR, Connor AJ, Guo Y, **Laskin JD**, **Laskin DL**. Activation of type II alveolar epithelial cells during acute endotoxemia. *Am J Physiol Lung Cell Mol Physiol.* 282:L872-L880, 2002.

Sunil VR, Connor AJ, Lavnikova N, Gardner CR, **Laskin JD**, **Laskin DL**. Acute endotoxemia prolongs the survival of rat lung neutrophils in response to 12-O-tetradecanoyl-phorbol 13-acetate. *J Cell Physiol.* 190:382-389, 2002.

Mariano TM, Vetrano AM, Gentile SL, Heck DE, Whittemore MS, Guillon CD, Jabin I, Rapp RD, Heindel ND, **Laskin JD**. Cell-impermeant pyridinium derivatives of psoralens as inhibitors of keratinocyte growth. *Biochem Pharmacol.* 63:31-39, 2002.

Matheson JM, Lemus R, Lange RW, Karol MH, **Luster MI**. Role of tumor necrosis factor in toluene diisocyanate asthma. *Am J Respir Cell Mol Biol.* 27:396-405, 2002.

Warren GL, Hulderman T, Jensen N, McKinstry M, Mishra M, **Luster MI**, Simeonova PP. Physiological role of tumor necrosis factor alpha in traumatic muscle injury. *FASEB J.* 16:1630-1632, 2002.

Scott AE, Kashon ML, Yucesoy B, **Luster MI**, **Tinkle SS**. Insights into the quantitative relationship between sensitization and challenge for allergic contact dermatitis reactions. *Toxicol Appl Pharmacol.* 183:66-70, 2002.

Sriram K, Matheson JM, Benkovic SA, Miller DB, **Luster MI**, O'Callaghan JP. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. *FASEB J.* 2002 Sep;16(11):1474-1476, 2002.

Simeonova PP, **Luster MI**. Arsenic carcinogenicity: relevance of c-Src activation. *Mol Cell Biochem.* 234-235:277-282, 2002.

Yucesoy B, Vallyathan V, Landsittel DP, Simeonova P, **Luster MI**. Cytokine polymorphisms in silicosis and other pneumoconioses. *Mol Cell Biochem.* 234-235:219-224, 2002.

Simeonova PP, Gallucci RM, Hulderman T, Wilson R, Kommineni C, Rao M, **Luster MI**. The role of tumor necrosis factor-alpha in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride. *Toxicol Appl Pharmacol.* 177:112-120, 2002.

Simeonova PP, Wang S, Hulderman T, **Luster MI**. c-Src-dependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic. Role in carcinogenesis. *J Biol Chem.* 277:2945-2950, 2002.

Sasaki K, Fan LW, Tien LT, **Ma T**, Loh HH, Ho IK. The interaction of morphine and gamma-aminobutyric acid (GABA)ergic systems in anxiolytic behavior: using mu-opioid receptor knockout mice. *Brain Res Bull* 57:689-694, 2002.

Fan LW, Tanaka S, Tien LT, **Ma T**, Rockhold RW, Ho IK. Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain. *Brain Res Bull* 58:149-160, 2002.

Zhai H, Simion FA, Abrutyn E, Koehler AM, **Maibach HI**. Screening topical antipruritics: a histamine-induced itch

human model. *Skin Pharmacol Appl Skin Physiol.* 15:213-217, 2002.

Hikima T, Yamada K, Kimura T, **Maibach HI**, Tojo K. Comparison of skin distribution of hydrolytic activity for bioconversion of beta-estradiol 17-acetate between man and several animals in vitro. *Eur J Pharm Biopharm.* 54:155-160, 2002.

Zhai H, Ebel JP, Chatterjee R, Stone KJ, Gartstein V, Juhlin KD, Pelosi A, **Maibach HI**. Hydration vs. skin permeability to nicotines in man. *Skin Res Technol.* 8:13-18, 2002.

Zhai H, **Maibach HI**. Occlusion vs. skin barrier function. *Skin Res Technol.* 8:1-6, 2002.

Jourdain R, Lacharriere O, Bastien P, **Maibach HI**. Ethnic variations in self-perceived sensitive skin: epidemiological survey. *Contact Dermatitis.* 46:162-169, 2002.

Levin C, **Maibach HI**. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. *Am J Clin Dermatol.* 3:141-147, 2002.

Poet TS, Weitz KK, Gies RA, Edwards JA, Thrall KD, Corley RA, Tanojo H, Hui X, **Maibach HI**, Wester RC. PBPK modeling of the percutaneous absorption of perchloroethylene from a soil matrix in rats and humans. *Toxicol Sci.* 67:17-31, 2002.

Levin CY, **Maibach HI**. Irritant contact dermatitis: is there an immunologic component? *Int Immunopharmacol.* 2:183-189, 2002.

Deleo VA, Taylor SC, Belsito DV, Fowler JF Jr, Fransway AF, **Maibach HI**, Marks JG Jr, Mathias CG, Nethercott JR, Pratt MD, Reitschel RR, Sherertz EF, Storrs FJ, Taylor JS. The effect of race and ethnicity on patch test results. *J Am Acad Dermatol.* 46:S107-S112, 2002.

Belsito DV, Fransway AF, Fowler JF Jr, Sherertz EF, **Maibach HI**, Marks JG Jr, Mathias CG, Rietschel RL, Storrs FJ, Nethercott JR. Allergic contact dermatitis to detergents: a multicenter study to assess prevalence. *J Am Acad Dermatol.* 46:200-206, 2002.

Hui X, Shainhouse Z, Tanojo H, Anigbogu A, Markus GE, **Maibach HI**, Wester RC. Enhanced human nail drug delivery: nail inner drug content assayed by new unique method. *J Pharm Sci.* 91:189-195, 2002.

McDougal JN, Boeniger MF. Methods for assessing risks of dermal exposures in the workplace. *Crit Rev Toxicol.* 32:291-327, 2002.

Poet TS, McDougal JN. Skin absorption and human risk assessment. *Chem Biol Interact.* 140:19-34, 2002.

McDougal JN, Robinson PJ. Assessment of dermal absorption and penetration of components of a fuel mixture (JP-8). *Sci Total Environ.* 288:23-30, 2002.

Meade BJ, Weissman DN, Beezhold DH. Latex allergy: past and present. *Int Immunopharmacol.* 2:225-38, 2002.

Riviere JE, Monteiro-Riviere NA, Baynes RE. Gulf War related exposure factors influencing topical absorption of 14C-permethrin. *Toxicol Lett.* 135:61-71, 2002.

Chou CC, **Riviere JE, Monteiro-Riviere NA**. Differential Relationship between the Carbon Chain Length of Jet Fuel Aliphatic Hydrocarbons and Their Ability to Induce Cytotoxicity vs. Interleukin-8 Release in Human Epidermal Keratinocytes. *Toxicol Sci.* 69:226-233, 2002.

Afaq F, **Mukhtar H**. Photochemoprevention by botanical antioxidants. *Skin Pharmacol Appl Skin Physiol.* 15:297-306, 2002.

Wang SI, **Mukhtar H**. Gene expression profile in human prostate LNCaP cancer cells by (-) epigallocatechin-3-gallate. *Cancer Lett.* 182:43-51, 2002.

An KP, Athar M, Tang X, Katiyar SK, Russo J, Beech J, Aszterbaum M, Kopelovich L, Epstein EH Jr, **Mukhtar H**, Bickers DR. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. *Photochem Photobiol.* 76:73-80, 2002.

Gupta S, **Mukhtar H**. Green tea and prostate cancer. *Urol Clin North Am.* 29:49-57, 2002.

Vaidya JS, **Mukhtar H**, Bryan R. Colonic metastasis from a breast cancer - a case report and a few questions. *Eur J Surg Oncol.* 28:463-464, 2002.

Singh AK, Seth P, Anthony P, Husain MM, Madhavan S, **Mukhtar H**, Maheshwari RK. Green tea constituent epigallocatechin-3-gallate inhibits angiogenic differentiation of human endothelial cells. *Arch Biochem Biophys.* 401:29-37, 2002.

Gupta S, Afaq F, **Mukhtar H**. Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. *Oncogene.* 21:3727-3738, 2002.

Wang SI, **Mukhtar H**. A high-efficiency translational control element

with potential for cancer gene therapy. *Int J Oncol.* 20:1269-1274, 2002.

Afaq F, Adhamsi VM, Ahmad N, **Mukhtar H**. Botanical antioxidants for chemoprevention of photocarcinogenesis. *Front Biosci.* 7:d784-d792, 2002.

Sarangapani R, Teeguarden J, **Plotzke KP**, McKim JM Jr, Andersen ME. Dose-response modeling of cytochrome p450 induction in rats by octamethylcyclotetrasiloxane. *Toxicol Sci.* 67:159-172, 2002.

Timchalk C, Kousba A, **Poet TS**. Monte Carlo analysis of the human chlorpyrifos-oxonase (PON1) polymorphism using a physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model. *Toxicol Lett.* 135:51-59, 2002.

Schlesinger RB, Cohen M, Gordon T, Nadziejko C, Zelikoff JT, Sisco M, **Regal JF**, Menache MG. Ozone-induced modulation of airway hyperresponsiveness in guinea pigs. *Res Rep Health Eff Inst.* 109:1-40; discussion 41-51, 2002.

Larsen CP, **Regal JF**. Trimellitic anhydride (TMA) dust induces airway obstruction and eosinophilia in non-sensitized guinea pigs. *Toxicology.* 178:89-99, 2002.

Schlesinger RB, Cohen MD, Gordon T, Nadziejko C, Zelikoff JT, Sisco M, **Regal JF**, Menache MG. Ozone differentially modulates airway responsiveness in atopic versus nonatopic guinea pigs. *Inhal Toxicol.* 14:431-457, 2002.

Larsen CP, **Regal JF**. Trimellitic anhydride-induced cellular infiltration into Guinea pig lung varies with age but not gender. *Int Arch Allergy Immunol.* 127:63-72, 2002.

Qiao GL, **Riviere JE**. Systemic uptake and cutaneous disposition of pentachlorophenol in a sequential exposure scenario: effects of skin preexposure to benzo[a]pyrene. *J Toxicol Environ Health A.* 65:1307-1331, 2002.

Martin-Jimenez T, **Riviere JE**. Mixed-effects modeling of the interspecies pharmacokinetic scaling of oxytetracycline. *J Pharm Sci.* 91:331-341, 2002.

Perkins MA, Cardin CW, Osterhues MA, **Robinson MK**. A non-invasive tape absorption method for recovery of inflammatory mediators to differentiate normal from compromised scalp conditions. *Skin Res Technol.* 8:187-193, 2002.

Robinson MK, Cohen C, de Fraissinette Ade B, Ponec M, Whittle E, Fentem JH. Non-animal testing strategies for assessment of the skin corrosion and skin irritation potential of ingredients and finished products. *Food Chem Toxicol.* 40:573-592, 2002.

Robinson MK. Population differences in acute skin irritation responses. Race, sex, age, sensitive skin and repeat subject comparisons. *Contact Dermatitis.* 46:86-93, 2002.

Kodithala K, Hopfinger AJ, Thompson ED, **Robinson MK**. Prediction of skin irritation from organic chemicals using membrane-interaction QSAR analysis. *Toxicol Sci.* 66:336-346.

Robinson MK, Perkins MA. A strategy for skin irritation testing. *Am J Contact Dermat.* 13:21-29.

Ryan LK, Copeland LR, Daniels MJ, Costa ER, Selgrade MJ. Proinflammatory and Th1 cytokine alterations following ultraviolet radiation enhancement of disease due to influenza infection in mice. *Toxicol Sci.* 67:88-97, 2002.

Sailstad DM. Murine local lymph node assay: an alternative test method for skin hypersensitivity testing. *Lab Anim (NY).* 31:36-41, 2002.

Plitnick LM, Loveless SE, Ladics GS, Holsapple MP, Selgrade MJ, **Sailstad DM**, Smialowicz RJ. Cytokine profiling for chemical sensitizers: application of the ribonuclease protection assay and effect of dose. *Toxicol Appl Pharmacol.* 179:145-154, 2002.

Tirmenstein MA, Hu CX, Gales TL, Maleeff BE, Narayanan PK, Kurali E, Hart TK, Thomas HC, **Schwartz LW**. Effects of Troglitazone on HepG2 Viability and Mitochondrial Function. *Toxicol Sci.* 69:131-138, 2002.

Kagan VE, Kisin ER, Kawai K, Serinkan BF, Osipov AN, **Serbinova EA**, Wolinsky I, **Shvedova AA**. Toward mechanism-based antioxidant interventions: lessons from natural antioxidants. *Ann N Y Acad Sci.* 959:188-198, 2002.

Shvedova AA, Kisin E, Murray A, Goldsmith T, Reynolds JS, Castranova V, Frazer DG, Kommineni C. Metal working fluids: sub-chronic effects on pulmonary functions in B6C3F1 mice given vitamin E deficient and sufficient diets. *Toxicology.* 177:285-297, 2002.

Modriansky M, Tyurina YY, Tyurin VA, Matsura T, **Shvedova AA**, Yalowich JC, Kagan VE. Anti-/pro-oxidant effects of phenolic compounds in cells: are colchicine metabolites chain-breaking antioxidants? *Toxicology.* 177:105-117,

2002.

Tyurina YY, Tyurin VA, **Shvedova AA**, Fabisiak JP, Kagan VE. Peroxidation of phosphatidylserine in mechanisms of apoptotic signaling. *Methods Enzymol.* 352:159-174, 2002.

Shvedova AA, Kisin E, Murray A, Smith C, Castranova V, Kommineni C. Enhanced oxidative stress in the skin of vitamin E deficient mice exposed to semisynthetic metal working fluids. *Toxicology.* 176:135-143, 2002.

Shvedova AA, Tyurina JY, Kawai K, Tyurin VA, Kommineni C, Castranova V, Fabisiak JP, Kagan VE. Selective peroxidation and externalization of phosphatidylserine in normal human epidermal keratinocytes during oxidative stress induced by cumene hydroperoxide. *J Invest Dermatol.* 118:1008-1018, 2002.

Tyurina YY, Tyurin VA, Liu SX, Smith CA, **Shvedova AA**, Schor NF, Kagan VE. Phosphatidylserine peroxidation during apoptosis. A signaling pathway for phagocyte clearance. *Subcell Biochem.* 36:79-96, 2002.

Johnson EA, **Shvedova AA**, Kisin E, O'Callaghan JP, Kommineni C, Miller DB. d-MDMA during vitamin E deficiency: effects on dopaminergic neurotoxicity and hepatotoxicity. *Brain Res.* 933:150-163, 2002.

Einspahr JG, **Stratton SP**, Bowden GT, Alberts DS. Chemoprevention of human skin cancer. *Crit Rev Oncol Hematol.* 41:269-285, 2002.

O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, **Stratton SP**, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. *Clin Cancer Res.* 8:314-346, 2002.